Ensil Canada Ltd. Announces the Validation of a 5-Minute, Non-Invasive HIV Test at its Laboratories in Ontario, Canada
MARKHAM, ON, February 10, 2012 -- After several years of scientific and biomedical laboratory experiments, Ensil succeeds in developing a nanotechnology-based sensor to detect GP21 and GP27 HIV virus through urine.
"After several years of scientific and biomedical laboratory experiments to develop nanotechnology-based sensors and detectors, we are extremely proud to make this announcement,” said Farsad Kiani, President and CEO of Ensil Group of Companies.
Mr. Kiani continued, "When the Ensil Canada Ltd. HIV diagnostic device is commercialized and put on the market, high-risk groups may get tested at more convenient locations as a do-it-yourself, real-time, cost-effective way to test and receive their own test results in strictest confidence.”
Ensil Canada Ltd. Chief Scientist and the Lead Project CSO added after the successful experiments with the antibody to HIV GP41, Ensil will try to validate the same results with its proprietary detection technology to detect GP120 so a wide range of HIV strain could be detected.
Ensil Canada Ltd., a member of Ensil group of companies (www.ensil.com) focuses on enhancing mission critical technologies in the areas of aerospace, defence, telecommunication and medical diagnostic equipment. Ensil’s R&D divisions’ mission is to develop new technologies or improve existing technologies through in-house research activities.
After nearly 30 years of scientific and technological experience, Ensil has required resources to modify, re-design, reverse engineer or repair circuit boards and assemblies used in medical, industrial and military equipment.
- Contact Information
- Louis Koikas
- VP Operation
- ENSIL CANADA LTD.
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.